Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 10:20PM GMT
Release Date Price: $8.2 (+6.08%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

All right, everyone. Thank you for joining us today at Goldman Sachs Global Healthcare Conference. Really excited to be joined by the team from Iovance Biotherapeutics. Great to be here and let's just get started.

All right. So let's start with kind of top of the mind on your lead program, your tumor-infiltrating lymphocyte, or TIL drug, lifileucel, in the upcoming BLA submission in post-PD-1 melanoma. So kind of proximal question, how are things proceeding? And really, what is the cadence of events between now and the BLA submission in August?

Questions & Answers

Jean;Marc Bellemin
Iovance Biotherapeutics, Inc. - CFO & Principal Accounting Officer

So let me take this one. Thank you, Madhu and thanks for the invite. Obviously, it's nice to be in person. So we're on track. I mean let's go short. We are on track to submit the BLA in August after pre-BLA meeting with the FDA in July, as we previously communicated. As you have seen last

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot